EUVIMEDEUVIMED entdecken
Crossref

Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy

Boda Guo iD, Feiya Yang, Lingpu Zhang, Qinxin Zhao, Wenkuan Wang, Lu Yin, Dong Chen, Mingshuai Wang, Sujun Han, Haihua Xiao iD, Nianzeng Xing iD

Advanced Materials · 2023-06 · 35 (22)

DOI: 10.1002/adma.202212267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 02.04.2023. Verfasst von Boda Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: Nanoparticles, Neoplasms. Die Arbeit wurde bisher 404-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: CAMS Initiative for Innovative Medicine, National Natural Science Foundation of China, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cuproptosis is a new cell death that depends on copper (Cu) ionophores to transport Cu into cancer cells, which induces cell death. However, existing Cu ionophores are small molecules with a short blood half‐life making it hard to transport enough Cu into cancer cells. Herein, a reactive oxygen species (ROS)‐sensitive polymer (PHPM) is designed, which is used to co‐encapsulate elesclomol (ES) and Cu to form nanoparticles (NP@ESCu). After entering cancer cells, ES and Cu, triggered by excessive intracellular ROS, are readily released. ES and Cu work in a concerted way to not only kill cancer cells by cuproptosis, but also induce immune responses. In vitro, the ability of NP@ESCu to efficiently transport Cu and induce cuproptosis is investigated. In addition, the change in the transcriptomes of cancer cells treated with NP@ESCu is explored by RNA‐Seq. In vivo, NP@ESCu is found to induce cuproptosis in the mice model with subcutaneous bladder cancer, reprograming the tumor microenvironment. Additionally, NP@ESCu is further combined with anti‐programmed cell death protein ligand‐1 antibody (αPD‐L1). This study provides the first report of combining nanomedicine that can induce cuproptosis with αPD‐L1 for enhanced cancer therapy, thereby providing a novel strategy for future cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesNeoplasmsAnimalsMiceCopperReactive Oxygen SpeciesImmunotherapyIonophoresApoptosisTumor MicroenvironmentHydrazines

Stichwörter der Autor:innen

cuproptosisimmunotherapynanoparticlestumor microenvironment

Substanzen

CopperReactive Oxygen SpeciesIonophoreselesclomolHydrazines

Autor:innen und Institutionen

  • Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, Chi…
  • Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
  • Department of Urology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, 030013, China.

ORCID-Profile: Boda Guo, Haihua Xiao, Nianzeng Xing

Förderung

  • CAMS Initiative for Innovative Medicine
  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • Capital Health Research and Development of Special Funding

Zitieren

APA

Guo, B., Yang, F., Zhang, L., Zhao, Q., Wang, W., Yin, L., Chen, D., Wang, M., Han, S., Xiao, H., & Xing, N. (2023). Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy. Advanced Materials, 35(22). https://doi.org/10.1002/adma.202212267

Vancouver

Guo B, Yang F, Zhang L, Zhao Q, Wang W, Yin L, et al. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy. Advanced Materials. 2023;35(22). doi:10.1002/adma.202212267

BibTeX
@article{Guo2023,
  author = {Guo, Boda and Yang, Feiya and Zhang, Lingpu and Zhao, Qinxin and Wang, Wenkuan and Yin, Lu and Chen, Dong and Wang, Mingshuai and Han, Sujun and Xiao, Haihua and Xing, Nianzeng},
  title = {Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2023},
  volume = {35},
  number = {22},
  doi = {10.1002/adma.202212267}
}
Kostenlos starten →